Patent US5035994A successfully refreshed from Google Patents.
US5035994A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Human stem cells and monoclonal antibodies
Assignee: Johns Hopkins University
•
Filing: 1990-09-07
•
Granted: 1991-07-30
•
Expires: 2010-09-07
Abstract
Abstract Monoclonal antibodies that recognize a stage-specific antigen on immature human marrow cells are provided. These antibodies are useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation. Cell suspensions containing human pluripotent lympho-hematopoietic stem cells are also provided, as well as therapeutic methods employing the cell suspensions.
Inventors
- 👤 Curt I. Civin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 10:32
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; Y; Y10; Y10S; Y10S530/00; Y10S530/808; Y10S530/809
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
142 words
A method of isolating a population of human cells containing pluripotent lympho-hematopoletic stem cells comprising: (a) providing a cell suspension from human tissue, said tissue selected from the group consisting of marrow and blood; (b) contacting said cell suspension with a monoclonal antibody to immature human marrow cells that is stage-specific and not lineage dependent so that said antibody binds to said stem cells, wherein said antibody specifically binds an antigen on human pluripotent lympho-hematopoletic stem cells said stem cells expressing an antigen that is specifically bound by the monoclonal antibody produced by the hybridomas deposited under ATCC Accession No. HB-8483 and does not specifically bind an antigen on mature, human myeloid and lymphoid cells; and (c) separating and recovering from said cell suspension the cells bound by said antibody, said bound cells being substantially free of nature lymphoid and myeloid cells.
Claim 2
Independent Claim
142 words
A method of isolating a population of human cells containing pluripotent lympho-hematopoletic stem cells comprising: (a) providing a cell suspension from human tissue, said tissue selected from the group consisting of marrow and blood; (b) contacting said cell suspension with a monoclonal antibody to immature human marrow cells that is stage-specific and not lineage dependent so that said antibody binds to said stem cells, wherein said antibody specifically binds an antigen on human pluripotent lympho-hematopoletic stem cells said stem cells expressing an antigen that is specifically bound by the monoclonal antibody produced by the hybridomas deposited under ATCC Accession No. HB-8483 and does not specifically bind an antigen on mature, human myeloid and lymphoid cells; and (c) separating and recovering from said cell suspension the cells bound by said antibody, said bound cells being substantially free of nature lymphoid and myeloid cells.
Claim 3
Dependent Claim
47 words
The method of claim 1 wherein said antibody specifically binds a cell-surface protein on a human leukemic cell line selected from the group consisting of the KG-1 and KG-1a cell lines, said protein having an apparent molecular weight of approximately 115 kD as determined by SDS-PAGE analysis.
Claim 4
Dependent Claim
29 words
The method of claim 1 wherein said antibody specifically binds an antigen also specifically bound by the monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-8483.
Claim 5
Dependent Claim
29 words
The method of claim 1 wherein said antibody corresponds to the monoclonal antibody produced by the hybridoma deposited under ATCC Accession No HB-8483 as demonstrated by binding inhibition assay.
Claim 6
Dependent Claim
19 words
The method of claim 1 wherein said antibody is produced by the hybridoma deposited under ATCC Accession No. HB-8483.
Claim 7
Independent Claim
154 words
A method of isolating a population of human cells containing pluripotent lympho-hematopoietic stem cells comprising: (a) providing a cell suspension from human tissue, said tissue selected from the group consisting of marrow and blood; (b) contacting said cell suspension with a solid-phase linked monoclonal antibody to immature human marrow cells that is stage-specific and not lineage-dependent so that said antibody binds to said stem cells, wherein said antibody specifically binds an antigen on human pluripotent lympho-hematopoietic stem cells, said stem cells expressing an antigen that is specifically bound by the monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-8483 but does not specifically bind an antigen on mature human myeloid and lymphoid cells; (c) separating unbound cells from said solid-state linked monoclonal antibody; and (d) recovering bound cells from said solid-phase linked monoclonal antibody after separating said unbound cells, said bound cells being substantially free of mature lymphoid and myeloid cells.
Claim 8
Independent Claim
154 words
A method of isolating a population of human cells containing pluripotent lympho-hematopoietic stem cells comprising: (a) providing a cell suspension from human tissue, said tissue selected from the group consisting of marrow and blood; (b) contacting said cell suspension with a solid-phase linked monoclonal antibody to immature human marrow cells that is stage-specific and not lineage-dependent so that said antibody binds to said stem cells, wherein said antibody specifically binds an antigen on human pluripotent lympho-hematopoietic stem cells, said stem cells expressing an antigen that is specifically bound by the monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-8483 but does not specifically bind an antigen on mature human myeloid and lymphoid cells; (c) separating unbound cells from said solid-state linked monoclonal antibody; and (d) recovering bound cells from said solid-phase linked monoclonal antibody after separating said unbound cells, said bound cells being substantially free of mature lymphoid and myeloid cells.
Claim 9
Dependent Claim
12 words
The method of claim 6 wherein said cell suspension is human blood.
Claim 10
Dependent Claim
43 words
The method of claim 7 wherein step (b) comprises continuously withdrawing blood from the circuitry system of a donor, passing said blood through a column containing said solid-phase linked monoclonal antibody, and then returning said blood to the circulatory system of said donor.
Claim 11
Dependent Claim
47 words
The method of claim 6 wherein said antibody specifically binds a cell-surface protein on a human leukemic cell line selected from the group consisting of the KG-1 and KG-1a cell lines, said antigen having an apparent molecular weight of approximately 115 kD as determined by SDS-PAGE analysis.
Claim 12
Dependent Claim
29 words
The method of claim 6 wherein said antibody specifically binds an antigen also specifically bound by the monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-8483.
Claim 13
Dependent Claim
29 words
The method of claim 8 wherein said antibody specifically binds an antigen also specifically bound by the monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-8483.
Claim 14
Dependent Claim
19 words
The method of claim 8 wherein said antibody is produced by the hybridoma deposited under ATCC Accession No. HB-8483.
References Cited (Backward Citations)
US4381295A
Cited
US4364932A
Cited
US4624925A
Cited
US4364937A
Cited
US4582797A
Cited
US4381292A
Cited
US4443427A
Cited
US4710457A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-07-29 | 1995-01-28 | 1995-07-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-07-29 | 1999-01-28 | 1999-07-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-07-29 | 2003-01-28 | 2003-07-30 | $7700.00 | Window Closed / Lapsed |